The US biosimilar market expands with new denosumab options, enhancing treatment for patients with osteoporosis and ...

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption ...

Number 5: Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory ...